Breaking Eight Dead in Billings Home Fire, Authorities Investigate as Homicide Meta Reaches Up To $18 Billion Settlement Over Lawsuit Alleging Addictive Platform Design Affecting Children NFL Confirms Ineligibility for Players Returning to College Dolly Parton’s Life and Career Featured in Visual Retrospective LIV Golf Announces Staff Reductions Amidst Shift from Saudi Funding

Wednesday August 26, 2026

Reporter

Vascarta Inc.

3Articles Published

5Communities Covered

Published Articles

Press Release

Vascarta Outlines VAS-101’s (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer

Aug 25

Press Release

Vascarta Outlines Proposed Mechanistic Link Between VAS-101’s (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease

Aug 20

Press Release

Vascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins

Aug 19